{
    "organizations": [],
    "uuid": "12ca6a0737c7f8d94033c02bc013debcdebc39f1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zealand-clinical-evidence-support/brief-zealand-clinical-evidence-support-potential-for-glepaglutide-idUSFWN1PI0BU",
    "ord_in_thread": 0,
    "title": "BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - ZEALAND PHARMA A/S:\n* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING\n* ‍IS ON TRACK TO INITIATE PHASE 3 IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-23T15:23:00.000+02:00",
    "crawled": "2018-01-24T15:21:08.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "zealand",
        "pharma",
        "zealand",
        "completed",
        "pharmacokinetic",
        "pk",
        "study",
        "glepaglutide",
        "confirms",
        "potential",
        "dosing",
        "track",
        "initiate",
        "phase",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}